Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
about
Acute murine colitis reduces colonic 5-aminosalicylic acid metabolism by regulation of N-acetyltransferase-2.Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis.Systematic review: the pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis.Randomised clinical trial: once- vs. twice-daily prolonged-release mesalazine for active ulcerative colitis.Crohn's is not a 6-week disease: lifelong management of mild to moderate Crohn's disease.Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX(®) mesalamine.Quality of life of patients with ulcerative colitis: past, present, and future.One-year investigator-blind randomized multicenter trial comparing Asacol 2.4 g once daily with 800 mg three times daily for maintenance of remission in ulcerative colitisMMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the treatment of ulcerative colitis.Patient considerations in the management of ulcerative colitis: role of once-daily MMX mesalamine.Once-daily dosing vs. conventional dosing schedule of mesalamine and relapse of quiescent ulcerative colitis: systematic review and meta-analysis.Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: a systematic review and meta-analysis.Systematic review of health-related quality of life measures for inflammatory bowel disease.Once daily vs multiple daily mesalamine therapy for mild to moderate ulcerative colitis: a meta-analysis.Comparative pharmacokinetics of equimolar doses of 5-aminosalicylate administered as oral mesalamine (Asacol) and balsalazide: a randomized, single-dose, crossover study in healthy volunteers.Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.Rectal tissue, plasma and urine concentrations of mesalazine after single and multiple administrations of 500 mg suppositories to healthy volunteers and ulcerative proctitis patients.Gastrointestinal transit and 5-ASA release from a new mesalazine extended-release formulation.Studies of compliance with delayed-release mesalazine therapy in patients with inflammatory bowel disease.Urinalysis of MMX-mesalazine as a tool to monitor 5-ASA adherence in daily IBD practice.Electronic Monitoring of Medication Adherence in a 1-year Clinical Study of 2 Dosing Regimens of Mesalazine for Adults in Remission with Ulcerative Colitis
P2860
Q33701611-11CD87E4-9D10-4A4D-9C5C-20AC7D7ED5CFQ34273329-CAC6D35F-37F3-46E1-AC6F-12DC656AE4BFQ34529943-E2B53B59-C8FA-4B4B-8D8B-42A82CB79B7CQ34648896-E0B1721A-1726-49B6-8FDA-974E5F87186AQ35913934-20C2FD3E-FEDD-45D3-8CAB-DF4C021E0936Q36144377-FC79B204-4AAF-4EB0-9632-4E4D99050A65Q36987080-19C8162D-8849-41DC-ABD9-E4F2C789232EQ37101734-41BE2A88-A6AA-4D14-9861-FF62B030901FQ37123430-67624F93-1112-4793-8FF6-E64A985052D8Q37423752-1FAC0220-22B2-4047-BADA-26E35E35F0B8Q37926915-DDEEEF06-B4FB-4AD1-9F78-FFFB64FF338AQ38014364-7A39DA04-60B7-4E99-91C1-3F722385D7F3Q38313606-360F3108-BB9C-494D-9767-0E6F36A3FA59Q38841927-FF85AB10-367B-4679-A9EB-5E781C3E1B1AQ42627096-0C118B03-8A56-4C86-B7D7-5B0BCE0D4C49Q42877648-901D3EF6-14CB-45A3-A580-2BB56CDA78D3Q44256477-F9AB9230-B2A6-4B44-97C0-58358B887656Q44299613-52A7B22A-FBCE-4EEF-8B45-0E5D5F74785AQ44517214-2AFCE6E5-10FE-4B91-8F09-2C873E5DF3C8Q48122081-48A7E96C-4377-4191-96CA-B140483BB51FQ57613900-76361934-ED32-46A9-B280-7855030FC319
P2860
Once versus divided daily dosing with delayed-release mesalazine: a study of tissue drug concentrations and standard pharmacokinetic parameters.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Once versus divided daily dosi ...... rd pharmacokinetic parameters.
@en
Once versus divided daily dosi ...... rd pharmacokinetic parameters.
@nl
type
label
Once versus divided daily dosi ...... rd pharmacokinetic parameters.
@en
Once versus divided daily dosi ...... rd pharmacokinetic parameters.
@nl
prefLabel
Once versus divided daily dosi ...... rd pharmacokinetic parameters.
@en
Once versus divided daily dosi ...... rd pharmacokinetic parameters.
@nl
P2093
P2860
P1476
Once versus divided daily dosi ...... rd pharmacokinetic parameters.
@en
P2093
P2860
P356
10.1046/J.1365-2036.2001.00891.X
P407
P577
2001-01-01T00:00:00Z